TSLP and skin disorder: Importantly, treatment with anti‐IL‐1β ‐antibody could alleviate MC903‐induced skin flares supporting findings that canakinumab can prevent TSLP release from keratinocytes.85 In a recent study, it was shown that 6‐8‐week‐old Flgft/ft mice without overt dermatitis constitutively expressed increased amounts of IL‐1α in the epidermis but 21 days after acute mechanical skin injury released less IL‐1α and more IL‐1β.86 These results indicate important, but divergent, roles for IL‐1 family cytokines in acute and chronic dermatitis.